Irene A Malaty, MD
Barbara Padgett Dein Professor Of Neurology, Director Of Parkinson Foundation Center Of Excellence And Tourette Association Of America Center For Excellence
Department:
MD-NEUROLOGY-MOVEMENT DISORDER
Business Phone:
(352) 273-5550
Business Email:
irene.malaty@neurology.ufl.edu
About Irene A Malaty
My name is Irene Malaty, MD, and I am a board-certified neurologist and movement disorders specialist at the Norman Fixel Institute for Neurological Diseases, serving as a professor in the University of Florida Department of Neurology.
I received my medical degree from Indiana University School of Medicine and completed my neurology residency and my movement disorders fellowship at UF.
I have been intrigued by the brain since I was young. Beginning in high school, I loved learning about how the brain controls our thoughts, speech and actions, and pondering the mysteries of how the mind operates. Parkinson’s disease also has a family connection for me as one of my favorite uncles lived with Parkinson’s disease.
In clinic, I see patients of all ages for various movement disorders, including Parkinson’s disease, Tourette syndrome and tic disorders, dystonia, essential tremor and atypical parkinsonism. My goal is to help people live their best life by listening to their concerns, educating them about their condition and treatment options and addressing the motor and non-motor (mood, cognitive and behavioral) symptoms of what is affecting them. We are a team, working together!
When I am not in clinic, I conduct research and clinical trials to learn more about people’s symptoms and to find better ways to treat movement disorders. Some research I have conducted includes exploring the use of pump-aided continuous levodopa infusion to avoid ups and downs of Parkinson’s medication, and trying out a novel botulinum toxin that could last up to twice as long as the options already on the market.
I also have projects looking at factors affecting individuals with tic disorders, including personal stressors, and a study looking at “dignity therapy” in people with advanced Parkinson’s disease to promote sense of purpose and value. I work together with researchers across the globe to explore hot topics in movement disorders such as unusual tic presentations during the COVID-19 pandemic.
I serve on the Science Committee of the American Academy of Neurology (AAN) and was selected for the inaugural class of the AAN’s Women Leading in Neurology program. I co-chair a task force to help shape the way doctors define and discuss tic disorders. I also teach about movement disorders internationally and co-authored “Living with Parkinson’s Disease.”
When I’m not at the clinic, I love traveling, viewing art and staying active by running and indoor cycling.
Accomplishments
Customer Service Key Award
2017
·
University of Florida
UF College of Medicine Clinical Outpatient Excellence Award
2017
·
University of Florida
UF College of Medicine Exemplary Teacher Award
2016
·
University of Florida
Customer Service Key Award
2014
·
University of Florida
UF College of Medicine Exemplary Teacher Award
2013
·
University of Florida
Clinical Educator of the Year Award
2012
·
University of Florida
Teaching Profile
Courses Taught
2021
MDC7800 Neurology Clerkship
Clinical Profile
Specialties
- Neurology
Areas of Interest
- Basal ganglia dysfunction
- Chronic motor or vocal tic disorder
- Deep brain stimulation
- Dystonia
- Essential tremor
- Movement – uncontrollable
- Movement – uncontrolled or slow
- Movement – uncoordinated
- Movement – unpredictable or jerky
- Obsessive-compulsive disorder
- Parkinson disease
- Progressive supranuclear palsy
- Tourette Syndrome and tic disorders
- Tremor disorders
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0001-6914-9223
Publications
2024
Diagnostic Criteria for Primary Tic Disorders: Time for Reappraisal
Movement Disorders.
39(8):1276-1281
[DOI] 10.1002/mds.29868.
2024
Longitudinal predictors of health-related quality of life in isolated dystonia.
Journal of neurology.
271(2):852-863
[DOI] 10.1007/s00415-023-12022-4.
[PMID] 37839041.
2024
Response to letter to the editor regarding “Does the 5-2-1 criteria identify patients with advanced Parkinson’s disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries”.
BMC neurology.
24(1)
[DOI] 10.1186/s12883-024-03691-3.
[PMID] 39080589.
2024
Sex Differences in Dystonia.
Movement disorders clinical practice.
11(8):973-982
[DOI] 10.1002/mdc3.14059.
[PMID] 38778444.
2023
An Empirical Comparison of Commonly Used Universal Rating Scales for Dystonia.
Movement disorders clinical practice.
10(12):1777-1786
[DOI] 10.1002/mdc3.13909.
[PMID] 38094647.
2023
Distinguishing functional from primary tics: a study of expert video assessments.
Journal of neurology, neurosurgery, and psychiatry.
94(9):751-756
[DOI] 10.1136/jnnp-2022-330822.
[PMID] 37169545.
2023
European Society for the Study of Tourette Syndrome 2022 criteria for clinical diagnosis of functional tic-like behaviours: International consensus from experts in tic disorders.
European journal of neurology.
30(4):902-910
[DOI] 10.1111/ene.15672.
[PMID] 36587367.
2023
Study protocol: A cross-sectional survey of clinicians to identify barriers to clinical practice guideline implementation in the assessment and treatment of persistent tic disorders.
PloS one.
18(7)
[DOI] 10.1371/journal.pone.0288408.
[PMID] 37467237.
2023
Treatment failure in persistent tic disorders: an expert clinicians’ consensus-based definition.
European child & adolescent psychiatry.
32(5):859-872
[DOI] 10.1007/s00787-021-01920-5.
[PMID] 34817664.
2022
Clinical Features and Evolution of Blepharospasm: A Multicenter International Cohort and Systematic Literature Review.
Dystonia (Lausanne, Switzerland).
1
[DOI] 10.3389/dyst.2022.10359.
[PMID] 36248010.
2022
Current Guidelines for Classifying and Diagnosing Cervical Dystonia: Empirical Evidence and Recommendations
Movement Disorders Clinical Practice.
9(2):183-190
[DOI] 10.1002/mdc3.13376.
[PMID] 35146058.
2022
Diagnosis and Management of Functional Tic-Like Phenomena
Journal of Clinical Medicine.
11(21)
[DOI] 10.3390/jcm11216470.
[PMID] 36362696.
2022
Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson’s Disease: A Placebo‐Controlled Trial of Rasagiline
Movement Disorders.
37(2):325-333
[DOI] 10.1002/mds.28838.
[PMID] 34724257.
2022
Does the 5-2-1 criteria identify patients with advanced Parkinson’s disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries.
BMC neurology.
22(1)
[DOI] 10.1186/s12883-022-02560-1.
[PMID] 35073872.
2022
Pediatric autoimmune Parkinsonism and response to deep brain stimulation.
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery.
38(1):203-206
[DOI] 10.1007/s00381-021-05152-5.
[PMID] 33830323.
2022
Subacute tremor and ataxia: Diligence in pursuit of a diagnosis.
Parkinsonism & related disorders.
104:129-131
[DOI] 10.1016/j.parkreldis.2022.05.016.
[PMID] 35718685.
2022
TANGO2 Mutation: A Genetic Cause of Multifocal Combined Dystonia
Movement Disorders Clinical Practice.
9(3):380-382
[DOI] 10.1002/mdc3.13400.
[PMID] 35402644.
2022
TikTok Tourette’s: Are We Witnessing a Rise in Functional Tic-Like Behavior Driven by Adolescent Social Media Use?
Psychology research and behavior management.
15:3575-3585
[DOI] 10.2147/PRBM.S359977.
[PMID] 36505669.
2022
Tourette Syndrome Treatment Updates: a Review and Discussion of the Current and Upcoming Literature.
Current neurology and neuroscience reports.
22(2):123-142
[DOI] 10.1007/s11910-022-01177-8.
[PMID] 35107785.
2021
A Multi‐center Genome‐wide Association Study of Cervical Dystonia
Movement Disorders.
36(12):2795-2801
[DOI] 10.1002/mds.28732.
[PMID] 34320236.
2021
An Update on Botulinum Toxin in Neurology.
Neurologic clinics.
39(1):209-229
[DOI] 10.1016/j.ncl.2020.09.014.
[PMID] 33223084.
2021
Clinical Practice Patterns in Tic Disorders Among Movement Disorder Society Members.
Tremor and other hyperkinetic movements (New York, N.Y.).
11
[DOI] 10.5334/tohm.656.
[PMID] 34754602.
2021
Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis.
Journal of managed care & specialty pharmacy.
27(6):785-790
[DOI] 10.18553/jmcp.2021.27.6.785.
[PMID] 34057395.
2021
Dystonia and Tremor: A Cross-Sectional Study of the Dystonia Coalition Cohort.
Neurology.
96(4):e563-e574
[DOI] 10.1212/WNL.0000000000011049.
[PMID] 33046615.
2021
Predictive modeling of spread in adult-onset isolated dystonia: Key properties and effect of tremor inclusion.
European journal of neurology.
28(12):3999-4009
[DOI] 10.1111/ene.15031.
[PMID] 34296504.
2021
Quality of life in isolated dystonia: non-motor manifestations matter.
Journal of neurology, neurosurgery, and psychiatry.
[DOI] 10.1136/jnnp-2020-325193.
[PMID] 33563813.
2021
Rhabdomyolysis secondary to severe tic fits.
BMJ case reports.
14(3)
[DOI] 10.1136/bcr-2020-239874.
[PMID] 33653856.
2021
Synaptic processes and immune-related pathways implicated in Tourette syndrome
Translational Psychiatry.
11(1)
[DOI] 10.1038/s41398-020-01082-z.
[PMID] 33462189.
2021
The 5 Pillars in Tourette Syndrome Deep Brain Stimulation Patient Selection: Present and Future.
Neurology.
96(14):664-676
[DOI] 10.1212/WNL.0000000000011704.
[PMID] 33593864.
2020
Case Report: Globus Pallidus Internus (GPi) Deep Brain Stimulation Induced Keyboard Typing Dysfunction.
Frontiers in human neuroscience.
14
[DOI] 10.3389/fnhum.2020.583441.
[PMID] 33240065.
2020
Clinical and Demographic Characteristics of Upper Limb Dystonia
Movement Disorders.
35(11):2086-2090
[DOI] 10.1002/mds.28223.
[PMID] 32845549.
2020
Deep Brain Stimulation for Tourette Syndrome: Potential Role in the Pediatric Population.
Journal of child neurology.
35(2):155-165
[DOI] 10.1177/0883073819872620.
[PMID] 31526168.
2020
Handwriting skills of children with tic disorders.
Australian occupational therapy journal.
67(6):563-571
[DOI] 10.1111/1440-1630.12686.
[PMID] 32656823.
2020
High-dose Botulinum Toxin Therapy: Safety, Benefit, and Endurance of Efficacy.
Tremor and other hyperkinetic movements (New York, N.Y.).
10
[DOI] 10.7916/tohm.v0.749.
[PMID] 32149014.
2020
Multidisciplinary Telemedicine Care for Tourette Syndrome: Minireview.
Frontiers in neurology.
11
[DOI] 10.3389/fneur.2020.573576.
[PMID] 33391146.
2020
Practical Evaluation and Management of Insomnia in Parkinson’s Disease: A Review.
Movement disorders clinical practice.
7(3):250-266
[DOI] 10.1002/mdc3.12899.
[PMID] 32258222.
2020
Straight from the Horse’s Mouth
Movement Disorders Clinical Practice.
7(S3)
[DOI] 10.1002/mdc3.13055.
[PMID] 33015226.
2019
Impact of dyskinesia on activities of daily living in Parkinson’s disease: Results from pooled phase 3 ADS-5102 clinical trials.
Parkinsonism & related disorders.
60:118-125
[DOI] 10.1016/j.parkreldis.2018.09.005.
[PMID] 30292734.
2019
Interrogating the Genetic Determinants of Tourette’s Syndrome and Other Tic Disorders Through Genome-Wide Association Studies.
The American journal of psychiatry.
176(3):217-227
[DOI] 10.1176/appi.ajp.2018.18070857.
[PMID] 30818990.
2019
Rescue levodopa-carbidopa intestinal gel (LCIG) therapy in Parkinson’s disease patients with suboptimal response to deep brain stimulation.
Annals of clinical and translational neurology.
6(10):1989-1995
[DOI] 10.1002/acn3.50889.
[PMID] 31518070.
2019
Tourette disorder and other tic disorders.
Handbook of clinical neurology.
165:123-153
[DOI] 10.1016/B978-0-444-64012-3.00008-3.
[PMID] 31727209.
2019
Tourette Syndrome has Substantial Impact in Childhood and Adulthood As Well.
Journal of developmental and behavioral pediatrics : JDBP.
40(6):468-469
[DOI] 10.1097/DBP.0000000000000699.
[PMID] 31318782.
2018
Analysis of shared heritability in common disorders of the brain.
Science (New York, N.Y.).
360(6395)
[DOI] 10.1126/science.aap8757.
[PMID] 29930110.
2018
Bilateral Basal Ganglia Necrosis Secondary to Methamphetamine.
Movement disorders clinical practice.
5(5):555-556
[DOI] 10.1002/mdc3.12649.
[PMID] 30515446.
2018
Efficacy and Safety of Deep Brain Stimulation in Tourette Syndrome: The International Tourette Syndrome Deep Brain Stimulation Public Database and Registry.
JAMA neurology.
75(3):353-359
[DOI] 10.1001/jamaneurol.2017.4317.
[PMID] 29340590.
2018
Predictors of alcohol responsiveness in dystonia
Neurology.
E2020-E2026
[DOI] 10.1212/WLM.0000000000006551.
2018
Predictors of alcohol responsiveness in dystonia.
Neurology.
91(21):e2020-e2026
[DOI] 10.1212/WNL.0000000000006551.
[PMID] 30341158.
2017
A Randomized Trial of Relamorelin for Constipation in Parkinson’s Disease (Move-Pd): Trial Results and Lessons Learned
Parkinsonism & Related Disorders.
37:101-105
[DOI] 10.1016/j.parkreldis.2017.02.003.
2017
Acute Parkinsonism and Basal Ganglia Damage from Crystal Methamphetamine.
Movement disorders clinical practice.
4(1):148-149
[DOI] 10.1002/mdc3.12439.
[PMID] 30713962.
2017
Botulinum Toxin Therapy for Parkinson’s Disease.
Seminars in neurology.
37(2):193-204
[DOI] 10.1055/s-0037-1602246.
[PMID] 28511260.
2017
Granulomatous meningitis secondary to Avitene (microfibrillar collagen).
Neurology. Clinical practice.
7(5):384-386
[DOI] 10.1212/CPJ.0000000000000305.
[PMID] 29620077.
2017
Psychiatric associations of adult-onset focal dystonia phenotypes.
Journal of neurology, neurosurgery, and psychiatry.
88(7):595-602
[DOI] 10.1136/jnnp-2016-315461.
[PMID] 28438790.
2017
Rare Copy Number Variants in NRXN1 and CNTN6 Increase Risk for Tourette Syndrome.
Neuron.
94(6):1101-1111.e7
[DOI] 10.1016/j.neuron.2017.06.010.
[PMID] 28641109.
2016
Clinical and demographic characteristics related to onset site and spread of cervical dystonia.
Movement disorders : official journal of the Movement Disorder Society.
31(12):1874-1882
[DOI] 10.1002/mds.26817.
[PMID] 27753188.
2016
Occurrence of Dysphagia Following Botulinum Toxin Injection in Parkinsonism-related Cervical Dystonia: A Retrospective Study.
Tremor and other hyperkinetic movements (New York, N.Y.).
6
[PMID] 27830106.
2016
The Danger of Not Treating Parkinson Disease Psychosis.
JAMA neurology.
73(9)
[DOI] 10.1001/jamaneurol.2016.2280.
[PMID] 27400122.
2015
Abnormal tactile pressure perception in Parkinson’s disease.
Journal of clinical and experimental neuropsychology.
37(8):808-15
[DOI] 10.1080/13803395.2015.1060951.
[PMID] 26313511.
2015
Global attentional neglect of segmented lines in Parkinson’s disease.
Neurocase.
21(4):501-8
[DOI] 10.1080/13554794.2014.942671.
[PMID] 25073971.
2015
How Should Pushing Off or the Use of Assistive Devices Be Incorporated in the Timed Up and Go for Persons With Parkinson Disease?
Archives of physical medicine and rehabilitation.
96(9):1728-32
[DOI] 10.1016/j.apmr.2015.03.021.
[PMID] 25883039.
2015
Person-Centered Care in the Home Setting for Parkinson’s Disease: Operation House Call Quality of Care Pilot Study.
Parkinson's disease.
2015
[DOI] 10.1155/2015/639494.
[PMID] 26078912.
2015
Rasagiline for the symptomatic treatment of fatigue in Parkinson’s disease.
Movement disorders : official journal of the Movement Disorder Society.
30(13):1825-30
[DOI] 10.1002/mds.26429.
[PMID] 26769459.
2015
The Profile of Long-term Parkinson’s Disease Survivors with 20 Years of Disease Duration and Beyond.
Journal of Parkinson's disease.
5(2):313-9
[DOI] 10.3233/JPD-140515.
[PMID] 25720446.
2015
Web-based phenotyping for Tourette Syndrome: Reliability of common co-morbid diagnoses.
Psychiatry research.
228(3):816-25
[DOI] 10.1016/j.psychres.2015.05.017.
[PMID] 26054936.
2015
Weight loss and impact on quality of life in Parkinson’s disease.
PloS one.
10(5)
[DOI] 10.1371/journal.pone.0124541.
[PMID] 25938478.
2014
An eight-year clinic experience with clozapine use in a Parkinson’s disease clinic setting.
PloS one.
9(3)
[DOI] 10.1371/journal.pone.0091545.
[PMID] 24646688.
2014
An independent elderly woman with rapid onset of coma.
JAMA neurology.
71(8):1043-7
[DOI] 10.1001/jamaneurol.2014.449.
[PMID] 24935802.
2014
Comparable Botulinum Toxin Outcomes between Primary and Secondary Blepharospasm: A Retrospective Analysis.
Tremor and other hyperkinetic movements (New York, N.Y.).
4
[DOI] 10.7916/D8H41Q4X.
[PMID] 25562037.
2014
Deep brain stimulation for tremor associated with underlying ataxia syndromes: a case series and discussion of issues.
Tremor and other hyperkinetic movements (New York, N.Y.).
4
[DOI] 10.7916/D8542KQ5.
[PMID] 25120941.
2014
Deep brain stimulation may improve quality of life in people with Parkinson’s disease without affecting caregiver burden.
Neuromodulation : journal of the International Neuromodulation Society.
17(2):126-32
[PMID] 24024760.
2014
Defining the clinically meaningful difference in gait speed in persons with Parkinson disease.
Journal of neurologic physical therapy : JNPT.
38(4):233-8
[DOI] 10.1097/NPT.0000000000000055.
[PMID] 25198866.
2014
Hypertensive urgency: an important aetiology of rebound hypertension.
BMJ case reports.
2014
[DOI] 10.1136/bcr-2014-206022.
[PMID] 25336552.
2014
Mobility, mood and site of care impact health related quality of life in Parkinson’s disease.
Parkinsonism & related disorders.
20(3):274-9
[DOI] 10.1016/j.parkreldis.2013.10.004.
[PMID] 24182524.
2014
Rescue GPi-DBS for a Stroke-associated Hemiballism in a Patient with STN-DBS.
Tremor and other hyperkinetic movements (New York, N.Y.).
4
[DOI] 10.7916/D8XP72WF.
[PMID] 24587970.
2014
The “brittle response” to Parkinson’s disease medications: characterization and response to deep brain stimulation.
PloS one.
9(4)
[DOI] 10.1371/journal.pone.0094856.
[PMID] 24733172.
2014
The Profile of Long-Term Parkinson’s Disease Survivors With 20 Years Disease Duration and Beyond
Movement Disorders.
29(14):1838-1839
2014
Timed up and go, cognitive, and quality-of-life correlates in Parkinson’s disease.
Archives of physical medicine and rehabilitation.
95(4):649-55
[DOI] 10.1016/j.apmr.2013.10.031.
[PMID] 24291596.
2014
Updates in medical and surgical therapies for Tourette syndrome.
Current neurology and neuroscience reports.
14(7)
[DOI] 10.1007/s11910-014-0458-4.
[PMID] 24871966.
2013
A Novel DYT-5 Mutation with Phenotypic Variability within a Colombian Family.
Tremor and other hyperkinetic movements (New York, N.Y.).
3
[DOI] 10.7916/D86W98SW.
[PMID] 24255805.
2013
A trial of scheduled deep brain stimulation for Tourette syndrome: moving away from continuous deep brain stimulation paradigms.
JAMA neurology.
70(1):85-94
[DOI] 10.1001/jamaneurol.2013.580.
[PMID] 23044532.
2013
Driving performance and behaviors: a comparison of gender differences in Parkinson’s disease.
Traffic injury prevention.
14(4):340-5
[DOI] 10.1080/15389588.2012.717730.
[PMID] 23531256.
2013
High rates and the risk factors for emergency room visits and hospitalization in Parkinson’s disease.
Parkinsonism & related disorders.
19(11):949-54
[DOI] 10.1016/j.parkreldis.2013.06.006.
[PMID] 23835430.
2013
Postural/Gait and cognitive function as predictors of driving performance in Parkinson’s disease.
Journal of Parkinson's disease.
3(2):153-60
[DOI] 10.3233/JPD-120152.
[PMID] 23938345.
2013
Smell and Taste Disorders in Primary Care
.
88(12):852-859
2013
Smell and taste disorders in primary care.
American family physician.
88(12):852-9
[PMID] 24364550.
2013
Taking a better history for behavioral issues pre- and post-deep brain stimulation: issues missed by standardized scales.
Neuromodulation : journal of the International Neuromodulation Society.
16(1):35-9; discussion 39
[DOI] 10.1111/j.1525-1403.2012.00477.x.
[PMID] 22748071.
2013
Using the Timed Up & Go test in a clinical setting to predict falling in Parkinson’s disease.
Archives of physical medicine and rehabilitation.
94(7):1300-5
[DOI] 10.1016/j.apmr.2013.02.020.
[PMID] 23473700.
2012
Are selective serotonin reuptake inhibitors associated with greater apathy in Parkinson’s disease?
The Journal of neuropsychiatry and clinical neurosciences.
24(3):326-30
[DOI] 10.1176/appi.neuropsych.11090210.
[PMID] 23037646.
2012
Clinical and Demographic Correlates of Antidepressant Utilisation in Parkinson’S Disease Population
.
78
2012
Depressive Symptoms in Parkinson Disease as Measured By Beck’S Depression Scale and Its Relationship To Visual Analogue Mood Scale, Motor Symptoms and the Quality of Life Measures
.
78
2012
Health comorbidities and cognition in 1948 patients with idiopathic Parkinson’s disease.
Parkinsonism & related disorders.
18(10):1073-8
[DOI] 10.1016/j.parkreldis.2012.06.004.
[PMID] 22776043.
2012
Improvement of both dystonia and tics with 60 Hz pallidal deep brain stimulation.
The International journal of neuroscience.
122(9):519-22
[DOI] 10.3109/00207454.2012.683219.
[PMID] 22494180.
2012
Mood and motor trajectories in Parkinson’s disease: multivariate latent growth curve modeling.
Neuropsychology.
26(1):71-80
[DOI] 10.1037/a0025119.
[PMID] 22142359.
2012
Quantitative normative gait data in a large cohort of ambulatory persons with Parkinson’s disease.
PloS one.
7(8)
[DOI] 10.1371/journal.pone.0042337.
[PMID] 22879945.
2012
What are the issues facing Parkinson’s disease patients at ten years of disease and beyond? Data from the NPF-QII study.
Parkinsonism & related disorders.
18 Suppl 3:S10-4
[DOI] 10.1016/j.parkreldis.2012.06.014.
[PMID] 22776044.
2011
Alternate but do not swim: a test for executive motor dysfunction in Parkinson disease.
Journal of the International Neuropsychological Society : JINS.
17(4):702-8
[DOI] 10.1017/S1355617711000609.
[PMID] 22882811.
2011
Binge eating in Parkinson’s disease: prevalence, correlates and the contribution of deep brain stimulation.
The Journal of neuropsychiatry and clinical neurosciences.
23(1):56-62
[PMID] 21304139.
2011
DBS candidates that fall short on a levodopa challenge test: alternative and important indications.
The neurologist.
17(5):263-8
[DOI] 10.1097/NRL.0b013e31822d1069.
[PMID] 21881468.
2011
Did General Douglas Macarthur Have Parkinson Disease? a Video and Archival Analysis
.
76:1668-1672
2011
Did General Douglas MacArthur have Parkinson disease? A video and archival analysis.
Neurology.
76(19):1668-72
[DOI] 10.1212/WNL.0b013e318219fb18.
[PMID] 21555736.
2011
Do stable patients with a premorbid depression history have a worse outcome after deep brain stimulation for Parkinson disease?
Neurosurgery.
69(2):357-60; discussion 360
[DOI] 10.1227/NEU.0b013e3182160456.
[PMID] 21415789.
2011
Effect of Deep Brain Stimulation on Parkinson’s Nonmotor Symptoms following Unilateral DBS: A Pilot Study.
Parkinson's disease.
2011
[DOI] 10.4061/2011/507416.
[PMID] 22220288.
2011
Hospitalization in Parkinson disease: a survey of National Parkinson Foundation Centers.
Parkinsonism & related disorders.
17(6):440-5
[DOI] 10.1016/j.parkreldis.2011.03.002.
[PMID] 21458353.
2011
Management of the hospitalized patient with Parkinson’s disease: current state of the field and need for guidelines.
Parkinsonism & related disorders.
17(3):139-45
[DOI] 10.1016/j.parkreldis.2010.11.009.
[PMID] 21159538.
2011
Measurement of patient-centered outcomes in Parkinson’s disease: what do patients really want from their treatment?
Parkinsonism & related disorders.
17(2):89-94
[DOI] 10.1016/j.parkreldis.2010.09.005.
[PMID] 20952243.
2011
Mixed results for GPi-DBS in the treatment of cranio-facial and cranio-cervical dystonia symptoms.
Journal of neurology.
258(11):2069-74
[DOI] 10.1007/s00415-011-6075-0.
[PMID] 21553081.
2011
Paroxysmal Kinesigenic Dyskinesia-like Symptoms in a Patient with Tourette Syndrome.
Tremor and other hyperkinetic movements (New York, N.Y.).
1
[DOI] 10.7916/D8XG9PWK.
[PMID] 23440654.
2011
Rescue leads: a salvage technique for selected patients with a suboptimal response to standard DBS therapy.
Parkinsonism & related disorders.
17(6):451-5
[DOI] 10.1016/j.parkreldis.2011.03.009.
[PMID] 21482169.
2011
Steady or not following thalamic deep brain stimulation for essential tremor.
Journal of neurology.
258(9):1643-8
[DOI] 10.1007/s00415-011-5986-0.
[PMID] 21442464.
2011
The distal partial trisomy 1q syndrome and dystonic tremor.
Parkinsonism & related disorders.
17(2):128-9
[DOI] 10.1016/j.parkreldis.2010.10.004.
[PMID] 21044857.
2011
The Frequency of Nonmotor Symptoms among Advanced Parkinson Patients May Depend on Instrument Used for Assessment.
Parkinson's disease.
2011
[DOI] 10.4061/2011/290195.
[PMID] 21808724.
2011
Unilateral GPi-DBS as a treatment for levodopa-induced respiratory dyskinesia in Parkinson disease.
The neurologist.
17(5):282-5
[DOI] 10.1097/NRL.0b013e318217367b.
[PMID] 21881473.
2011
Usefulness of screening tools for predicting driving performance in people with Parkinson’s disease.
The American journal of occupational therapy : official publication of the American Occupational Therapy Association.
65(5):579-88
[PMID] 22026326.
2010
A closer look at unilateral versus bilateral deep brain stimulation: results of the National Institutes of Health COMPARE cohort.
Journal of neurosurgery.
113(6):1224-9
[DOI] 10.3171/2010.8.JNS10312.
[PMID] 20849215.
2010
An evaluation of rating scales utilized for deep brain stimulation for dystonia.
Journal of neurology.
257(1):44-58
[DOI] 10.1007/s00415-009-5261-9.
[PMID] 19639382.
2010
Are Results From Pd Trials Generalizable? the Npf Database Reveals a Mismatch Between Typical Clinic Populations and Subjects in Pd Trials
Movement Disorders.
25
2010
Brain penetration effects of microelectrodes and deep brain stimulation leads in ventral intermediate nucleus stimulation for essential tremor.
Journal of neurosurgery.
112(3):491-6
[DOI] 10.3171/2009.7.JNS09150.
[PMID] 19663554.
2010
Clonazepam and botulinum toxin for the treatment of alien limb phenomenon.
The neurologist.
16(2):106-8
[DOI] 10.1097/NRL.0b013e3181a0d670.
[PMID] 20220444.
2010
Differential response of dystonia and parkinsonism following globus pallidus internus deep brain stimulation in X-linked dystonia-parkinsonism (Lubag).
Stereotactic and functional neurosurgery.
88(5):329-33
[DOI] 10.1159/000319961.
[PMID] 20714213.
2010
Is rhinorrhea an under-recognized intrinsic symptom of Parkinson disease? A prospective pilot study.
The International journal of neuroscience.
120(4):258-60
[DOI] 10.3109/00207451003615755.
[PMID] 20374072.
2010
Mood and motor effects of thalamic deep brain stimulation surgery for essential tremor.
European journal of neurology.
17(8):1040-6
[DOI] 10.1111/j.1468-1331.2010.02958.x.
[PMID] 20113336.
2010
Piloting the NPF data-driven quality improvement initiative.
Parkinsonism & related disorders.
16(8):517-21
[DOI] 10.1016/j.parkreldis.2010.06.005.
[PMID] 20609611.
2010
The impact of and the factors associated with drooling in Parkinson’s disease.
Parkinsonism & related disorders.
16(7):475-7
[DOI] 10.1016/j.parkreldis.2009.12.003.
[PMID] 20064737.
2010
The number and nature of emergency department encounters in patients with deep brain stimulators.
Journal of neurology.
257(1):122-31
[DOI] 10.1007/s00415-009-5343-8.
[PMID] 19813069.
2010
The relationship between anosmia, constipation, and orthostasis and Parkinson’s disease duration: results of a pilot study.
The International journal of neuroscience.
120(1):67-70
[DOI] 10.3109/00207450903337721.
[PMID] 20128674.
2009
Brain penetration effects of microelectrodes and DBS leads in STN or GPi.
Journal of neurology, neurosurgery, and psychiatry.
80(7):794-7
[DOI] 10.1136/jnnp.2008.159558.
[PMID] 19237386.
2009
Effects of dopaminergic medication on objective tasks of deftness, bradykinesia and force control.
Journal of neurology.
256(12):2030-5
[DOI] 10.1007/s00415-009-5235-y.
[PMID] 19597692.
2009
Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study.
The International journal of neuroscience.
119(12):2196-205
[DOI] 10.3109/00207450903222758.
[PMID] 19916848.
2009
Role of rasagiline in treating Parkinson’s disease: Effect on disease progression.
Therapeutics and clinical risk management.
5(4):413-9
[PMID] 19753135.
Grants
Dec 2023
ACTIVE
Parkinsons Foundation FY24 Center of Excellence Award
Role: Principal Investigator
Funding: PARKINSONS FOU
Jun 2023
ACTIVE
Parkinsons Foundation PD GENEration Genetic Registry
Role: Principal Investigator
Funding: PARKINSONS FOU
Jun 2023
ACTIVE
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Maintenance of Efficacy of Ecopipam in Children, Adolescents and Adults with Tourettes Disorder
Role: Principal Investigator
Funding: EMALEX BIOSCIENCES
Jun 2023
ACTIVE
AN OPEN-LABEL STUDY OF THE LONG-TERM SAFETY AND TOLERABILITY OF SAGE-324 IN PARTICIPANTS WITH ESSENTIAL TREMOR
Role: Principal Investigator
Funding: SYNEOS HEALTH
via SAGE THERAPEUTICS INC
Feb 2023
ACTIVE
A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RESPONSE STUDY OF SAGE-324 FOR THE TREATMENT OF ESSENTIAL TREMOR
Role: Principal Investigator
Funding: SYNEOS HEALTH
via SAGE THERAPEUTICS INC
Jan 2023
– Jul 2023
UF CoE Community Education Grant (TAA) 2023
Role: Principal Investigator
Funding: TOURETTE ASSOCIATION OF AMERICA
via CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2022
ACTIVE
Progressive resistance exercise and dystonia pathophysiology.
Role: Co-Investigator
Funding: NATL INST OF HLTH NINDS
Jul 2022
– Jun 2023
Parkinson Foundation Center of Excellence 2022-2023
Role: Principal Investigator
Funding: PARKINSONS FOU
Jul 2022
– May 2023
PF COE PCORI Addtl. Support
Role: Principal Investigator
Funding: PARKINSONS FOU
Jun 2022
ACTIVE
CTOA Malaty
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Oct 2021
– Jun 2022
Parkinsons Foundation Center of Excellence Palliative Care Training Grant Award
Role: Principal Investigator
Funding: PARKINSONS FOU
Jul 2021
– Jun 2022
Parkinson's Foundation COE award
Role: Principal Investigator
Funding: PARKINSONS FOU
Jun 2021
– Aug 2022
Parkinsons Disease Outreach Program to African Americans in Alachua County
Role: Principal Investigator
Funding: PARKINSONS FOU
Sep 2020
– Nov 2022
An Open-Label Extension Of Study M15-736 To Evaluate The Safety And Tolerability Of 24-Hour Daily Exposure Of ABBV-951 In Subjects With Advanced Parkinson's Disease
Role: Principal Investigator
Funding: ABBVIE
Jul 2020
ACTIVE
A multicenter, randomized, active-controlled, double-blind, double dummy,
parallel group clinical trial, investigating the efficacy, safety,
and tolerability of continuous subcutaneous ND0612 infusion in
comparison to oral IR-LD/CD in subjects with Parkinsons disease
experiencing motor fluctuations (BouNDless)
Role: Principal Investigator
Funding: SYNEOS HEALTH
via NEURODERM
Jul 2020
– Jun 2021
Parkinson Foundation Center of Excellence 2020-2021
Role: Principal Investigator
Funding: PARKINSONS FOU
Feb 2020
– Jun 2022
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients
Role: Principal Investigator
Funding: ABBVIE
Dec 2019
– Dec 2024
A Randomized, Double-Blind, Placebo Controlled Multiple Ascending
Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics,
Pharmacodynamics and Immunogenicity of ABBV-0805 in Patients with Parkinson's Disease
Role: Principal Investigator
Funding: ABBVIE
Aug 2019
– Sep 2021
A 14-Week, Double-Blind, Randomized, Three-Arm, Parallel Group Study
to Assess the Efficacy and Safety of Two Doses of Pridopidine versus
Placebo for the Treatment of Levodopa-Induced Dyskinesia in Patients
with Parkinsons Disease (gLIDe)
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC
via PRILENIA THERAPEUTICS
Jul 2019
– Jun 2020
2020 Educational Partnership Symposium COE
Role: Principal Investigator
Funding: PARKINSONS FOU
Jul 2019
– Jun 2020
Parkinson Foundation Center of Excellence 2019-2020
Role: Principal Investigator
Funding: PARKINSONS FOU
Feb 2019
– Feb 2023
A Phase 3, Open-Label, Multi-Center Trial to Evaluate the Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults with Isolated Cervical Dystonia (ASPEN-OLS)
Role: Principal Investigator
Funding: GREENPHIRE
via REVANCE THERAPEUTICS
Feb 2019
– Jan 2021
An Open-Label, Long-Term Safety Study Including a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents
Role: Principal Investigator
Funding: SYNEOS HEALTH
via TEVA PHARMACEUTICALS USA
Jan 2019
– Sep 2021
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a Single Treatment of DaxibotulinumtoxinA for Injection in Adults with Isolated Cervical Dystonia (ASPEN-1)
Role: Principal Investigator
Funding: GREENPHIRE
via REVANCE THERAPEUTICS
Jan 2019
– Oct 2021
Evaluation of oral anti-Parkinsonian medication use in patients with advanced Parkinson's Disease with history of Deep Brain Stimulation (DBS) and being treated with carbidopa levodopa enteral suspension (CLES)
Role: Principal Investigator
Funding: WORLDWIDE CLINICAL TRIALS
via ABBVIE
Dec 2018
– Aug 2019
Southeast Area Centers of Excellence 2019
Role: Principal Investigator
Funding: TOURETTE ASSOCIATION OF AMERICA
Nov 2018
– Nov 2023
A well-controlled fixed dose study of TEV-50717 (deutetrabenazine) for treatment of Tics associated with Tourette Syndrome
Role: Principal Investigator
Funding: SYNEOS HEALTH
via TEVA PHARMACEUTICALS USA
Jul 2018
– Dec 2019
Parkinson Foundation Center of Excellence 2018-2019
Role: Principal Investigator
Funding: PARKINSONS FOU
Apr 2018
– Aug 2018
SE Regional Centers of Excellence Community Outreach & Education Advocacy Program
Role: Principal Investigator
Funding: TOURETTE ASSOCIATION OF AMERICA
Jun 2017
– Jun 2018
Parkinson Foundation Center of Excellence
Role: Principal Investigator
Funding: NATL PARKINSON FOU
Apr 2017
– Apr 2023
Caregiving in Parkinsons Disease Project
Role: Principal Investigator
Funding: PARKINSONS FOU
Jan 2017
– Jan 2020
A clinical study of patients with symptomatic neuRogenic orthostatic
hypotEnsion to assess Sustained effecTs Of dRoxidopa thErapy
Role: Principal Investigator
Funding: LUNDBECK NA LTD
Oct 2016
– Oct 2019
NBI-98854-1601: An Open-Label, Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects with Tourette Syndrome
Role: Principal Investigator
Funding: NEUROCRINE BIOSCIENCES
Aug 2016
– May 2023
Scaling and Sequencing Motor Output in Humans: fMRI Study
Role: Co-Investigator
Funding: NATL INST OF HLTH NINDS
Jul 2016
– Jul 2018
A 15-Week, Phase II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study to Investigate the Efficasy, Safety and Tolerability of PF-06649751 in Subjects with Motor Fluctuations Due to Idiopathic Parkinson's Disease
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC
via PFIZER INC
Jul 2016
– Jun 2023
The Human Thalamocortical Network in tourette syndrome
Role: Co-Investigator
Funding: NATL INST OF HLTH NINDS
Jul 2016
– Jun 2017
National Parkinson Foundation (NPF) Center of Excellence
Role: Principal Investigator
Funding: NATL PARKINSON FOU
Apr 2016
– Apr 2019
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO ASSESSTHE SAFETY AND EFFICACY OF NBI-98854 IN ADULT SUBJECTS WITH
Role: Principal Investigator
Funding: NEUROCRINE BIOSCIENCES
Feb 2016
– Feb 2019
Prevalence of TD and tics among a community-recruited sample of adults from Haiti
Role: Project Manager
Funding: TOURETTE ASSOCIATION OF AMERICA
Jan 2016
– Mar 2018
A Randomized, Double-Blind, Placebo-Controlled Study to Asses the Safety and Efficacy of NBI-98854 in Pediatric Subjects with Tourette Syndrome
Role: Principal Investigator
Funding: NEUROCRINE BIOSCIENCES
Dec 2015
– Jan 2021
GLobal OBservational Study Evaluating Long-Term Effectiveness (DUOGLOBE)
Role: Principal Investigator
Funding: ABBVIE
Oct 2015
– Oct 2018
a phase 3 multicenter randomized double blind
Role: Principal Investigator
Funding: INVENTIV HEALTH CLINICAL LLC
via BIOTIE THERAPIES
Sep 2015
– Jul 2018
An Open Label Extension Study to Investigate the Long Term Safety, Tolerability, and Efficacy of PF-02545920 in Subjects with Huntingtons Disease who Previously Completed Study A8241021.
Role: Principal Investigator
Funding: INVENTIV HEALTH CLINICAL LLC
via PFIZER INC
Sep 2015
– Jan 2022
Dystonia Coalition Projects
Role: Principal Investigator
Funding: DYSTONIA MEDICAL RES FOU
via NATL INST OF HLTH NCATS
Jul 2015
– Jun 2017
Center of Excellence 2015-2016
Role: Principal Investigator
Funding: NATL PARKINSON FOU
Nov 2014
– Nov 2017
A PHASE 2, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND PROOF-OF-CONCEPT STUDY OF THE EFFICACY AND SAFETY OF PF-02545920 IN SUBJECTS WITH HUNTINGTONS DISEASE
Role: Principal Investigator
Funding: INVENTIV HEALTH CLINICAL LLC
Nov 2014
– Oct 2018
TSA Centers of Excellence for Tourette Syndrome & Tic Disorders
Role: Principal Investigator
Funding: TOURETTE ASSOCIATION OF AMERICA
Sep 2014
– Sep 2017
OPEN-LABEL SAFETY STUDY OF ADS-5102 (AMANTADINE HCL) EXTENDED RELEASE CAPSULES FOR THE TREATMENT OF LEVODOPA INDUCED DYSKINESIA
Role: Principal Investigator
Funding: ADAMAS PHARMACEUTICALS
Aug 2014
– Aug 2017
EFFICACY AND SAFETY OF ADS-5102 (AMANTADINE HCL) EXTENDED RELEASE CAPSULES FOR THE TREATMENT OF LEVODOPA INDUCED DYSKINESIA IN PARKINSONS DISEASE PATIENTS (EASE LID STUDY)
Role: Principal Investigator
Funding: ADAMAS PHARMACEUTICALS
Aug 2014
– Aug 2017
A pilot study of SD-809 (deutetrabenazine) in moderate to severe Tourette Syndrome
Role: Principal Investigator
Funding: AUSPEX PHARMACEUTICALS
Dec 2013
– Mar 2016
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Parallel Group Study to Evaluate the Pharmacodynamics, Efficacy and Safety of RM-131 Administered to Patients with Parkinsons Disease
Role: Principal Investigator
Funding: RHYTHM PHARMACEUTICALS
Jul 2013
– Dec 2017
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF SD-809 EXTENDED RELEASE FOR THE TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTON DISEASE
Role: Principal Investigator
Funding: AUSPEX PHARMACEUTICALS
May 2013
– Dec 2016
An Open-Label, Two Part, Multicenter Study to Assess the Safety and Efficacy of Levodopa Carbidopa Intestinal Gel (LCIG) for the Treatment of Non-Motor Symptoms in Subjects with Advanced Parkinsons Disease
Role: Principal Investigator
Funding: ABBVIE
Jun 2012
– Jun 2018
CD FLEX: An Open-Label, Non-Inferiority Study Evaluating the Efficacy and Safety of Two Injection Schedules of Xeomin? (incobotulinumtoxinA) [Short Flex vs. Long Flex] in Subjects with Cervical Dystonia
Role: Principal Investigator
Funding: MERZ PHARMACEUTICALS GMBH
Jun 2010
– May 2024
Quality Improvement Initiative (QII) Phase II
Role: Principal Investigator
Funding: PARKINSONS FOU
Nov 2009
– Sep 2017
Open-Label Continuation Treatment Study with Levodopa-Carbidopa Intestinal Gel in Subjects with Advanced Parkinson's Disease and Severe Motor Fluctuations who have exhibited a persistent and positive effort to treatment in previous studies
Role: Principal Investigator
Funding: IQVIA Holdings
Contact Details
Phones:
- Business:
- (352) 273-5550
Emails:
- Business:
- irene.malaty@neurology.ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100268
GAINESVILLE FL 32610 - Business Street:
-
3011 SW WILLISTON RD RM 1103
GAINESVILLE FL 32608